Background-We report hypertrophic cardiomyopathy (HCM) in a Spanish-American family caused by a novel ␣-tropomyosin (TPM1) mutation and examine the pathogenesis of the clinical disease by characterizing functional defects in the purified mutant protein. Methods and Results-HCM was linked to the TPM1 gene (logarithm of the odds [LOD] score 3.17). Sequencing and restriction digestion analysis demonstrated a TPM1 mutation V95A that cosegregated with HCM. The mutation has been associated with 13 deaths in 26 affected members (11 sudden deaths and 2 related to heart failure), with a cumulative survival rate of 73Ϯ10% at the age of 40 years. Left ventricular wall thickness (mean 16Ϯ6 mm) and disease penetrance (53%) were similar to those for the ␤-myosin mutations L908V and G256E previously associated with a benign prognosis. Left ventricular hypertrophy was milder than with the ␤-myosin mutation R403Q, but the prognosis was similarly poor. With the use of recombinant tropomyosins, we identified several functional alterations at the protein level. The mutation caused a 40% to 50% increase in calcium affinity in regulated thin filament-myosin subfragment-1 (S1) MgATPase assays, a 20% decrease in MgATPase rates in the presence of saturating calcium, a 5% decrease in unloaded shortening velocity in in vitro motility assays, and no change in cooperative myosin S1 binding to regulated thin filaments. Conclusions-In contrast to other reported TPM1 mutations, V95A-associated HCM exhibits unusual features of mild phenotype but poor prognosis. Both myosin cycling and calcium binding to troponin are abnormal in the presence of the mutant tropomyosin. The genetic diagnosis afforded by this mutation will be valuable in the management of HCM. (Circulation. 2001;103:65-71.)
H ypertrophic cardiomyopathy (HCM) is characterized by left ventricular (LV) hypertrophy (LVH) and myocyte disarray. Clinical characteristics of HCM vary from a benign asymptomatic course to severe heart failure and sudden death. Molecular genetic studies [1] [2] [3] [4] [5] [6] [7] have shown that HCM may be caused by mutations in several sarcomeric genes, including TPM1, that may determine clinical outcome. Most ␤-myosin heavy chain gene (MYH7) mutations, such as R403Q, are associated with high disease penetrance and a poor prognosis. 4 In contrast, the few MYH7 mutations that have a benign prognosis, such as L908V and G256E, are associated with a low disease penetrance. 5 HCM caused by myosin-binding protein-C gene (MYBPC3) is characterized by low disease penetrance (Ϸ60%), mild cardiac phenotype in young sub-jects, and a favorable prognosis. [1] [2] [3] HCM due to cardiac troponin-T gene (TNNT2) is usually associated with relatively low disease penetrance (Ϸ80%) and mild LVH but a high incidence of sudden death. 6 The TPM1 gene consists of 14 exons and 4 isoforms (␣and ␤-tropomyosins, tropomyosin-4, and tropomyosin-30). 1, 8 The cardiac isoform is generated from 10 exons, is expressed in both myocardium and fast skeletal muscle fibers, and consists of 284 amino acids. 8 Tropomyosin, actin, and troponin complex (troponins T, C, and I) make up most of the thin filament in striated muscle. Tropomyosin is a rigid, rodlike protein that binds along the length of the actin filament and is intimately associated with troponin complex. 9 It adds to the rigidity and stability of the thin filament. In the absence of Ca 2ϩ binding to troponin C, ␣-tropomyosin inhibits the binding of myosin to actin. Binding of Ca 2ϩ to troponin C results in the release of myosin-binding site of actin by the tropomyosin-troponin complex. The interaction of actin and myosin heads then generates contractile force. 9, 10 Mutations in TPM1 account for Ϸ3% of cases of HCM. [11] [12] [13] [14] Four TPM1 mutations have been described: A63V, K70T, D175N, and E180G. The first 2 mutations are located in exon 2b in an area that may alter the binding of ␣-tropomyosin to actin, and the latter 2 mutations are located in exon 5 near a Ca 2ϩ -dependent troponin-T binding domain.
We report here a novel TPM1 missense mutation with the unique features of mild cardiac hypertrophy but a high mortality rate. We also describe the properties of the isolated mutant protein, which exhibits fundamental defects in regulatory function.
Methods

Research Subjects
We identified HCM in a large Spanish-American family (Figure 1 ). Seventy-four family members were enrolled in the studies. Informed consent for the genetic studies was obtained under a protocol approved by the Institutional Review Board of the National Heart, Lung, and Blood Institute.
Genetic Studies
Linkage analysis was performed with markers from the ABI screening set 2 15 and MLINK module of the LINKAGE 5.2 program. 16 Sequences from exon 1 to exon 9a,b of TPM1 were amplified from genomic DNA with primers as previously described 17 for 2 affected and 2 control individuals. To confirm segregation of the mutation in the family and absence of the mutation in normal subjects, amplified exon 3 fragments were digested with restriction endonuclease DdeI (Boehringer-Mannheim) and analyzed by electrophoresis through a 2% agarose gel.
Clinical Studies
Studies included 2D echocardiography, 12-lead ECG, and in selected cases, treadmill exercise test, exercise thallium scintigraphy, MRI, cardiac catheterization, and angiography. We also reviewed the clinical records, death certificates, and autopsy reports of 6 family members who died suddenly.
HCM was defined as LV wall thickness Ͼ13 mm in the absence of another cause for the LVH. Disease penetrance was defined as number of family members with HCM divided by the number of family members with the mutation.
The findings were compared with those previously reported for the MYH7 mutations L908V, G256E, and R403Q with well-defined clinical characteristics. 4, 5 
Biochemical Studies
Polymerase chain reaction-based mutagenesis of Ala-Ser rat striated muscle ␣-tropomyosin 18 was performed as described previously 19 to produce cDNA encoding the V95A mutation. The fidelity of the entire coding sequence was confirmed by automated DNA sequencing. As previously for other recombinant tropomyosins, wild-type and mutant tropomyosins were expressed in DE3 cells with the pET3d expression vector 20 and then purified to homogeneity. 20 Purified actin, 21 myosin subfragment-1 (S1), 22 and troponin 23 were obtained as described previously.
Thin filament-myosin S1 MgATPase rates were determined by release of 32 P-P i from ATP, 24, 25 and the free calcium concentration was manipulated with mixtures of CaCl 2 and di-bromo BAPTA. 26 MgATPase data as a function of the free calcium concentration were analyzed according to equation 12 in Tobacman and Sawyer, 26 using Scientist for nonlinear least squares fitting. We determined in vitro motility by labeling reconstituted regulated thin filaments with rhodamine-phalloidin and monitoring their movement over a rabbit skeletal heavy meromyosin-coated surface using epifluorescence microscopy and quantitative analysis of motion. 27, 28 Actin-myosin S1 binding was monitored by steady-state fluorescence with pyrenelabeled actin as described by Criddle et al 29 and Rosol et al. 30 These data were analyzed according to the model of Hill et al 31 for cooperative myosin binding to the thin filament, using Scientist for nonlinear least squares curve fitting.
Statistics
Patient data are presented as meanϮSD. Differences for mean values of maximum LV wall thickness were compared by Student's t test. Cumulative survival was determined by product-limit survival analysis with sudden death as the time variable. The log-rank test was used to compare actuarial survival curves. A 2-tailed value of PϽ0.05 was considered significant.
Results
Genetic Results
The TPM1 marker D15S127 gave a 2-point LOD score of 3.17 in 24 members of the family. A heterozygous base change from T to C was observed at nucleotide position 340 (cDNA sequence of the TPM1, GenBank accession No. M19713) in exon 3 from 2 affected individuals ( Figure 2A) . A change from a valine to alanine in amino acid residue 95 of the protein is predicted as a result of this change. The mutation adds a recognition site for the restriction endonuclease DdeI and changes the restriction digestion pattern of amplified exon 3 fragments ( Figure 2B ). Restriction digestion was performed to detect the mutation in 56 family members.
All family members who were diagnosed with HCM had the V95A mutation. The mutation was not detected in the 200 unrelated normal individuals.
Cardiac Phenotype
The data of 26 affected family members were examined. The individuals included all 14 members positive for the mutation, 11 additional members who died of the disease, and an affected family member for whom no DNA was available. The area of maximum LV wall thickness was localized to posterior basal wall, anterolateral free wall, and/or apex in 9 patients. None of the patients had LV outflow obstruction.
Maximum LV wall thickness was 16Ϯ6 mm (range 8 to 27 mm). MRI-aided diagnosis of HCM as LVH was very localized in some patients.
The ECG was abnormal in 11 (79%) of 14 affected family members, but only 6 (43%) showed LVH by voltage criteria. Eight (57%) of the 14 affected members showed ST-T-wave abnormalities. Two subjects with LV wall thickness of 10 and 13 mm, respectively, developed significant ST-wave depression during treadmill test but had normal coronary angiograms. Figure 3 shows the relation between maximum LV wall thickness and age in the family members. The maximum LV wall thickness was Ͻ12 mm in all adult members without the mutation. LVH and disease penetrance (53%, 8 of a total of 15 affected members in whom echocardiograms were available) were similar to subjects with the MYH7 mutations G256E and L908V (Figure 4 ). LVH and penetrance were significantly less than in the MYH7 mutation R403Q.
Disease Penetrance
Prognosis
LV systolic dysfunction was noted in 5 patients; 3 were complicated by symptomatic bradycardia or cardiac arrest, and 2 are asymptomatic. There have been 13 deaths: 11 sudden deaths and 2 related to heart failure. Four of the sudden deaths were related to physical activity; 2 occurred in subjects with mild or no LVH. An additional patient has presyncope with exertion. Cumulative survival rates have been 73Ϯ10% and 32Ϯ13% at 40 and 60 years of age, respectively. The survival rate was worse than that for the MYH7 mutations L908V and G256E and similar to that for the MYH7 mutation R403Q ( Figure 5 ).
Effect of the Mutation on Protein Function
Effect of the Mutation on Calcium-Sensitive Regulation of Acto-Myosin S1
To understand how the mutation acts to produce the observed clinical phenotype, control and mutant tropomyosins were expressed in bacteria and their properties studied in detail. Previous studies of HCM tropomyosin mutants 175 and 180 suggested that these alterations increased the calcium sensitivity of muscle contraction in fibers or cells containing mixtures of normal and mutant molecules. 32, 33 This effect has not been demonstrated in a purified reconstituted system for any HCM tropomyosin mutation. Thin filaments were reconstituted with actin, troponin, and recombinant tropomyosin, and a biochemical correlate of muscle regulation was evaluated: calcium-sensitive regulation of myosin S1 MgATPase activity. Representative data are shown in Figure 6 . The V95A mutation resulted in abnormal regulation, characterized most notably by increased calcium affinity. To examine this more precisely, multiple experiments performed as in Figure 6 showed a 40% to 50% increase in apparent calcium affinity, from 3.2Ϯ0.5 to 5.0Ϯ0.7ϫ10 5 M -1 , a 0.2 pCa shift. Also, Figure 6 suggests and additional determinations confirmed that the maximum MgATPase rate in the presence of saturating calcium was diminished from 2.95Ϯ0.20 to 2.28Ϯ0.18 s -1 , a 22Ϯ6% decrease in paired studies (nϭ5). This small but reproducible effect implies an effect of the mutation on myosin cycling. There were no statistically significant effects on the cooperativity of activation (Yϭ13Ϯ4 for control and 8Ϯ3 for V95A where YϷn H 19,26 ) or on the ATPase rate in the absence of calcium (0.24Ϯ0.05 versus 0.25Ϯ0.02 s -1 ) (Figure 7) .
Effect on In Vitro Motility
To determine whether the mutation altered mechanical actinmyosin function, the in vitro motility of control and mutant filaments was examined. Wild-type or mutant tropomyosincontaining actin-troponin-tropomyosin filaments were combined with rhodamine-phalloidin, and their unloaded sliding over a heavy meromyosin-coated surface was measured. 27 The data were analyzed 2 ways: for all of the observed filaments, and for the subset of filaments that moved over the surface at a continuous, smooth speed. In either case, the effect of the mutations was a small decrease (5%) in the maximum sliding speed in the presence of saturating calcium (Table) . The large values of n (range 179 to 232) resulted in low standard errors for these measurements. (Standard deviation values are shown in the Table) . Both control and mutant filaments were highly regulated by calcium: in the presence of calcium, 90% of the filaments moved smoothly and rapidly, whereas in the absence of calcium, Ͻ2% moved smoothly and did so at speeds that were decreased by 90%. These in vitro motility data are consistent with the MgAT-Pase data; the mutation produces subtle alterations in myosin cycling but does not prevent regulation.
Effect on Myosin Cross-Bridge Binding to the Filament
The above effects could in principle be due to altered myosin binding to thin filaments containing the mutant tropomyosin. To evaluate this, actin was labeled on Cys374 with n-(1pyrenyl)iodoacetamide, and binding of myosin S1-ADP to thin filaments was monitored by steady-state fluorescence. Thin filaments containing pyrene actin, troponin, and either wild-type or mutant tropomyosin were examined in the presence or absence of calcium. In both cases, tropomyosin had no effect on the myosin-binding isotherm ( Figures 7A  and 7B) , indicating that the V95A mutation does not alter myosin binding to the thin filament.
Discussion
We identified a Spanish-American family with HCM caused by a novel TPM1 mutation V95A that was associated with several abnormalities of tropomyosin function, a low disease penetrance, and a mild and unusual distribution of LVH, yet a poor prognosis.
V95A Mutation in TPM1 and ␣-Tropomyosin Function
That the TPM1 mutation V95A causes HCM is supported by several observations. First, linkage analysis showed a statistically significant linkage of the disease locus to chromosome 15q22. Second, the mutation was present in all clinically affected family members but not in 200 normal individuals Figure 7 . Myosin S1 binding to thin filaments containing normal and mutant tropomyosins. Thin filaments containing actin, troponin, and either wild-type (circles) or V95A (triangles) tropomyosin were examined in either presence (A) or absence (B) of calcium. In both panels, titrations are indistinguishable for the 2 tropomyosins, indicating that V95A tropomyosin mutation does not alter myosin binding to thin filament. Binding is more cooperative in absence of calcium (B). Conditions: 25°C, 20 mmol/L imidazole (pH 7.5), 125 mmol/L KCl, 5 mmol/L MgCl 2 , 1 mmol/L dithiothreitol, 2 mmol/L ADP, 1 mol/L actin, 0.5 mol/L troponin, 0.5 mol/L tropomyosin, 0.2 mg/mL bovine serum albumin, 14 U/mL hexokinase, 1 mmol/L glucose, 20 mol/L Ap5A, 0.5 mmol/L EGTA, and (B only) 0.6 mmol/L CaCl 2 . Lines are based on best fit parameters, with affinity constant Kϭ2.31Ϯ0.06 and 2.30Ϯ0.08ϫ10 6 mol/L Ϫ1 for control and mutant tropomyosins in presence of calcium and 2.38Ϯ0.06 and 2.29Ϯ0.03 in absence of calcium. Figure 6 . Effects of V95A TPM1 mutation on thin filament-myosin S1 MgATPase rate regulation with purified recombinant proteins. This representative experiment shows calcium-sensitive regulation of thin filament-activated myosin S1 ATP hydrolysis in presence of either normal (circles) or mutant (triangles) thin filaments in presence of calcium. Note left shift in curve when thin filaments contain mutant tropomyosin, showing increased apparent calcium affinity, from 3.4Ϯ0.2ϫ10 5 mol/L Ϫ1 to 4.7Ϯ0.3ϫ10 5 mol/L Ϫ1 in this experiment. Also, maximum rate in presence of saturating calcium was 10% less when mutation was present. Conditions: 25°C, 7 mol/L F-actin, 1 mol/L tropomyosin, 1 mol/L troponin, 0.3 mol/L myosin S1, 20 mmol/L imidazole (pH 7.5), 3.5 mmol/L MgCl 2 , 7 mmol/L KCl, 1 mmol/L dithiothreitol. Plotted rates are moles of P i per mole of myosin S1 per second.
(400 chromosomes; population frequency Ͻ0.25%). In addition, the mutated valine residue has been highly conserved in vertebrates throughout evolution.
In a series of recent articles, 18, 19, 30 a region of tropomyosin that includes the site of the V95A mutation has been implicated as critical for thin filament activation. Preceding structural work 34 -36 suggested that the thin filament has 3 conformations: (1) without Ca 2ϩ bound to troponin, and with tropomyosin blocking the myosin binding site on actin;
(2) with Ca 2ϩ bound to the troponin, causing tropomyosin movement on actin to partially expose the binding site for myosin; and (3) a third (fully active) conformation in which myosin is bound and the tropomyosin moves further. 37 Tropomyosin residues 89 to 207 appear to be critical for stabilizing this final state of the thin filament, which is required for thin filament activation. The V95A mutation may alter 1 or more transitions among these states.
Similarly, tropomyosin HCM mutations at positions D175N and E180G have been proposed to alter thin filament activation, 38, 39 although neither myosin affinity nor Ca 2ϩ affinity was examined for these mutants. Functional studies of TPM1 cDNA expressed in skeletal muscle and those performed on single skinned skeletal fibers from transgenic animals and affected patients demonstrated increased Ca 2ϩ sensitivity. 32, 39, 40 Furthermore, adenovirus-mediated expression of several HCM-causing tropomyosins at the 35% level in adult cardiac myocytes resulted in Ca 2ϩ -sensitizing effects on force, 33 with severity dependent on the mutation. Figures  6 and 7 in the present work show a similar effect under highly defined conditions using purified proteins and demonstrate that the effect is not due to increased myosin binding. By implication, it is calcium affinity per se that is altered for this mutation. Michele et al 33 suggested that the severity of the calcium-sensitizing effect may correlate with clinical severity. However, the clinical severity of the V95A patients is particularly high, yet the alteration in Ca 2ϩ sensitivity for reconstituted 100% mutant filaments ( Figure 6 ) is no greater than that observed for 35% mutant fibers. 33 Altered myosin cycling ( Figure 6 , the Table) may also be an important contributor to disease pathogenesis.
Cardiac Phenotype and Prognosis
Clinical characteristics and prognosis associated with mutations of TPM1 have not been well characterized owing to small size and composition of affected families. In previous reports, HCM caused by the TPM1 mutation D175N showed a variable phenotype with a good prognosis. 14 The TPM1 mutation E180G has been associated with mild LVH, but the prognosis is unclear. 17 Few HCM cases caused by the TPM1 mutations A63V and K70T have been reported: mild LVH associated with sudden death, congestive heart failure, and LV dilatation. 12, 13 In the present kindred, the mean maximum LV wall thickness was 16Ϯ6 mm in the 15 affected members. The presence of cardiomyopathy was indicated by abnormal ECG in several carriers of the mutation in the absence of LVH. Conversely, ECG criteria cannot be used to diagnose the V95A mutation, because a number of affected family members did not have classic ECG features associated with HCM. However, under the age of 50 years, an abnormal ECG often indicated disease in the absence of LVH. The distribution of LVH was unusual. Although the disease penetrance was only 53%, overall, clinical features of this TPM1 mutation V95A, including LVH, LV dysfunction, and sudden death, were observed in 85% of the affected members. Although clinical and genetic data were not available in several of the deceased family members, the history of sudden death at young ages provided compelling evidence that the events were related to the disease mutation. Notably, the clinical expression and calcium sensitivity of TPM1 mutation V95A are similar to HCM caused by TNNT2 mutations associated with similarly poor prognosis. 41 Genotyping is important for definitive diagnosis, because the myopathy is associated with atypical findings. Detection of the TPM1 mutation V95A is important for early counseling and treatment of family members. 42 Tn indicates bovine cardiac troponin; Tm, control or mutant tropomyosin; n, number of filaments characterized. (The large values of n result in low standard errors for these measurements.) Rhodamine-phalloidin labeled actin-troponin-tropomyosin filaments were injected into the motility chamber under the following conditions: 25°C, 100 mmol/L ionic strength, 140 mmol/L MOPS (pH 7.4), 1 mmol/L MgCl 2 , 1 mmol/L ATP, 10 mmol/L KCl, 2 mmol/L (K/Ca) EGTA, and 100 mmol/L troponin and tropomyosin.
Effect of TPM1 V95A Mutation on
